The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Ryaltris 25 microgram/actuation + 600 microgram/actuation nasal spray, suspension

Glenmark Pharmaceuticals s.r.o.PA1543/002/001

Main Information

Trade NameRyaltris 25 microgram/actuation + 600 microgram/actuation nasal spray, suspension
Active SubstancesMometasone furoate
Dosage FormNasal spray, suspension
Licence HolderGlenmark Pharmaceuticals s.r.o.
Licence NumberPA1543/002/001

Group Information

ATC CodeR01AD59 mometasone, combinations


License statusAuthorised
Licence Issued16/07/2021
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back